Heterogeneous responses of an in vitro model of human stomach cancer to anticancer drugs

S. C. Barranco, Courtney Townsend, M. A. Quraishi, N. L. Burger, H. C. Nevill, K. H. Howell, W. R. Boerwinkle

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Four permanent clones of a human adenocarcinoma of the stomach and the parent line from which they were isolated were used as an in vitro model system to evaluate the effects of 8 anticancer agents on cell survival. The drugs tested were actinomycin D (Act-D), Bleomycin (Bleo), adriamycin (adria), melphalan, chlorambucil, 5 Fluorouracil (5FU), 1,2:5,6-Dianhydrogalactitol (DAG), and 1-(2-chloroethyl)-3-(4-methyl cyclohexyl-1-nitrosurea) (MeCCNU). Although the cell lines had similar growth properties, morphologies and modal chromosome numbers, the clones expressed heterogeneous survival responses to each of six drugs tested. A comparison of the doses lethal to 90% of a clonal population (LD90) for each drug indicated large differences between the most sensitive and least sensitive clones. For chlorambucil there was a 160% difference between the LD90 values of the most and least sensitive clones. For MeCCNU the difference was 200%; for adria, 230%; Bleo, 280%; 5FU, 360%; and melphalan, 600%. Despite the heterogeneity in response among the clones to these agents, no particular clone was always the most sensitive or resistant. Of particular interest was the finding that these stomach cancer clones demonstrated uniform responses to both Act-D and DAG. Since the differential drug sensitivities expressed by heterogeneous tumor populations could be a cause of treatment failure in the patient, the demonstration of uniform sensitivities to Act-D and DAG are encouraging and suggest that other anticancer drugs which produce uniform cell killing may be identified and tested. Act-D and adria were the most effective of the drugs tested when compared on a dose for dose basis. Both agents killed more than 99.9% of the parent cell line with doses below 3 μg/ml (1-h treatments). The cells were least sensitive to 5FU, with only 30% of the cells killed at 100 μg/ml. The studies reported here indicate that this human stomach cancer model can provide valuable insight into the design of clinical protocols for treatment of gastric carcinoma in man.

Original languageEnglish (US)
Pages (from-to)117-127
Number of pages11
JournalInvestigational New Drugs
Volume1
Issue number2
DOIs
StatePublished - Jun 1983

Fingerprint

Stomach Neoplasms
Clone Cells
Dianhydrogalactitol
Dactinomycin
Pharmaceutical Preparations
Fluorouracil
Doxorubicin
Chlorambucil
Melphalan
Bleomycin
Stomach
Cell Line
Clinical Protocols
In Vitro Techniques
Treatment Failure
Antineoplastic Agents
Population
Cell Survival
Adenocarcinoma
Chromosomes

Keywords

  • differential drug sensitivities
  • heterogeneous human tumor clones
  • resistance
  • sensitivity
  • uniform killing

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Barranco, S. C., Townsend, C., Quraishi, M. A., Burger, N. L., Nevill, H. C., Howell, K. H., & Boerwinkle, W. R. (1983). Heterogeneous responses of an in vitro model of human stomach cancer to anticancer drugs. Investigational New Drugs, 1(2), 117-127. https://doi.org/10.1007/BF00172070

Heterogeneous responses of an in vitro model of human stomach cancer to anticancer drugs. / Barranco, S. C.; Townsend, Courtney; Quraishi, M. A.; Burger, N. L.; Nevill, H. C.; Howell, K. H.; Boerwinkle, W. R.

In: Investigational New Drugs, Vol. 1, No. 2, 06.1983, p. 117-127.

Research output: Contribution to journalArticle

Barranco, SC, Townsend, C, Quraishi, MA, Burger, NL, Nevill, HC, Howell, KH & Boerwinkle, WR 1983, 'Heterogeneous responses of an in vitro model of human stomach cancer to anticancer drugs', Investigational New Drugs, vol. 1, no. 2, pp. 117-127. https://doi.org/10.1007/BF00172070
Barranco, S. C. ; Townsend, Courtney ; Quraishi, M. A. ; Burger, N. L. ; Nevill, H. C. ; Howell, K. H. ; Boerwinkle, W. R. / Heterogeneous responses of an in vitro model of human stomach cancer to anticancer drugs. In: Investigational New Drugs. 1983 ; Vol. 1, No. 2. pp. 117-127.
@article{6d87bdf26f404c0f964da39e4a516df9,
title = "Heterogeneous responses of an in vitro model of human stomach cancer to anticancer drugs",
abstract = "Four permanent clones of a human adenocarcinoma of the stomach and the parent line from which they were isolated were used as an in vitro model system to evaluate the effects of 8 anticancer agents on cell survival. The drugs tested were actinomycin D (Act-D), Bleomycin (Bleo), adriamycin (adria), melphalan, chlorambucil, 5 Fluorouracil (5FU), 1,2:5,6-Dianhydrogalactitol (DAG), and 1-(2-chloroethyl)-3-(4-methyl cyclohexyl-1-nitrosurea) (MeCCNU). Although the cell lines had similar growth properties, morphologies and modal chromosome numbers, the clones expressed heterogeneous survival responses to each of six drugs tested. A comparison of the doses lethal to 90{\%} of a clonal population (LD90) for each drug indicated large differences between the most sensitive and least sensitive clones. For chlorambucil there was a 160{\%} difference between the LD90 values of the most and least sensitive clones. For MeCCNU the difference was 200{\%}; for adria, 230{\%}; Bleo, 280{\%}; 5FU, 360{\%}; and melphalan, 600{\%}. Despite the heterogeneity in response among the clones to these agents, no particular clone was always the most sensitive or resistant. Of particular interest was the finding that these stomach cancer clones demonstrated uniform responses to both Act-D and DAG. Since the differential drug sensitivities expressed by heterogeneous tumor populations could be a cause of treatment failure in the patient, the demonstration of uniform sensitivities to Act-D and DAG are encouraging and suggest that other anticancer drugs which produce uniform cell killing may be identified and tested. Act-D and adria were the most effective of the drugs tested when compared on a dose for dose basis. Both agents killed more than 99.9{\%} of the parent cell line with doses below 3 μg/ml (1-h treatments). The cells were least sensitive to 5FU, with only 30{\%} of the cells killed at 100 μg/ml. The studies reported here indicate that this human stomach cancer model can provide valuable insight into the design of clinical protocols for treatment of gastric carcinoma in man.",
keywords = "differential drug sensitivities, heterogeneous human tumor clones, resistance, sensitivity, uniform killing",
author = "Barranco, {S. C.} and Courtney Townsend and Quraishi, {M. A.} and Burger, {N. L.} and Nevill, {H. C.} and Howell, {K. H.} and Boerwinkle, {W. R.}",
year = "1983",
month = "6",
doi = "10.1007/BF00172070",
language = "English (US)",
volume = "1",
pages = "117--127",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Heterogeneous responses of an in vitro model of human stomach cancer to anticancer drugs

AU - Barranco, S. C.

AU - Townsend, Courtney

AU - Quraishi, M. A.

AU - Burger, N. L.

AU - Nevill, H. C.

AU - Howell, K. H.

AU - Boerwinkle, W. R.

PY - 1983/6

Y1 - 1983/6

N2 - Four permanent clones of a human adenocarcinoma of the stomach and the parent line from which they were isolated were used as an in vitro model system to evaluate the effects of 8 anticancer agents on cell survival. The drugs tested were actinomycin D (Act-D), Bleomycin (Bleo), adriamycin (adria), melphalan, chlorambucil, 5 Fluorouracil (5FU), 1,2:5,6-Dianhydrogalactitol (DAG), and 1-(2-chloroethyl)-3-(4-methyl cyclohexyl-1-nitrosurea) (MeCCNU). Although the cell lines had similar growth properties, morphologies and modal chromosome numbers, the clones expressed heterogeneous survival responses to each of six drugs tested. A comparison of the doses lethal to 90% of a clonal population (LD90) for each drug indicated large differences between the most sensitive and least sensitive clones. For chlorambucil there was a 160% difference between the LD90 values of the most and least sensitive clones. For MeCCNU the difference was 200%; for adria, 230%; Bleo, 280%; 5FU, 360%; and melphalan, 600%. Despite the heterogeneity in response among the clones to these agents, no particular clone was always the most sensitive or resistant. Of particular interest was the finding that these stomach cancer clones demonstrated uniform responses to both Act-D and DAG. Since the differential drug sensitivities expressed by heterogeneous tumor populations could be a cause of treatment failure in the patient, the demonstration of uniform sensitivities to Act-D and DAG are encouraging and suggest that other anticancer drugs which produce uniform cell killing may be identified and tested. Act-D and adria were the most effective of the drugs tested when compared on a dose for dose basis. Both agents killed more than 99.9% of the parent cell line with doses below 3 μg/ml (1-h treatments). The cells were least sensitive to 5FU, with only 30% of the cells killed at 100 μg/ml. The studies reported here indicate that this human stomach cancer model can provide valuable insight into the design of clinical protocols for treatment of gastric carcinoma in man.

AB - Four permanent clones of a human adenocarcinoma of the stomach and the parent line from which they were isolated were used as an in vitro model system to evaluate the effects of 8 anticancer agents on cell survival. The drugs tested were actinomycin D (Act-D), Bleomycin (Bleo), adriamycin (adria), melphalan, chlorambucil, 5 Fluorouracil (5FU), 1,2:5,6-Dianhydrogalactitol (DAG), and 1-(2-chloroethyl)-3-(4-methyl cyclohexyl-1-nitrosurea) (MeCCNU). Although the cell lines had similar growth properties, morphologies and modal chromosome numbers, the clones expressed heterogeneous survival responses to each of six drugs tested. A comparison of the doses lethal to 90% of a clonal population (LD90) for each drug indicated large differences between the most sensitive and least sensitive clones. For chlorambucil there was a 160% difference between the LD90 values of the most and least sensitive clones. For MeCCNU the difference was 200%; for adria, 230%; Bleo, 280%; 5FU, 360%; and melphalan, 600%. Despite the heterogeneity in response among the clones to these agents, no particular clone was always the most sensitive or resistant. Of particular interest was the finding that these stomach cancer clones demonstrated uniform responses to both Act-D and DAG. Since the differential drug sensitivities expressed by heterogeneous tumor populations could be a cause of treatment failure in the patient, the demonstration of uniform sensitivities to Act-D and DAG are encouraging and suggest that other anticancer drugs which produce uniform cell killing may be identified and tested. Act-D and adria were the most effective of the drugs tested when compared on a dose for dose basis. Both agents killed more than 99.9% of the parent cell line with doses below 3 μg/ml (1-h treatments). The cells were least sensitive to 5FU, with only 30% of the cells killed at 100 μg/ml. The studies reported here indicate that this human stomach cancer model can provide valuable insight into the design of clinical protocols for treatment of gastric carcinoma in man.

KW - differential drug sensitivities

KW - heterogeneous human tumor clones

KW - resistance

KW - sensitivity

KW - uniform killing

UR - http://www.scopus.com/inward/record.url?scp=0020954328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020954328&partnerID=8YFLogxK

U2 - 10.1007/BF00172070

DO - 10.1007/BF00172070

M3 - Article

C2 - 6678861

AN - SCOPUS:0020954328

VL - 1

SP - 117

EP - 127

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -